BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26390240)

  • 1. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay.
    Alix-Panabières C; Pantel K
    Expert Rev Mol Diagn; 2015; 15(11):1411-7. PubMed ID: 26390240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Studies on Viable Circulating Tumor Cells.
    Pantel K; Alix-Panabières C
    Clin Chem; 2016 Feb; 62(2):328-34. PubMed ID: 26637479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EpCAM-Independent Enrichment and Detection of Viable Circulating Tumor Cells Using the EPISPOT Assay.
    Soler A; Cayrefourcq L; Mazel M; Alix-Panabières C
    Methods Mol Biol; 2017; 1634():263-276. PubMed ID: 28819858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional studies on circulating and disseminated tumor cells in carcinoma patients.
    Alix-Panabières C; Bartkowiak K; Pantel K
    Mol Oncol; 2016 Mar; 10(3):443-9. PubMed ID: 26847851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients.
    Alix-Panabières C
    Recent Results Cancer Res; 2012; 195():69-76. PubMed ID: 22527495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cells in lung cancer.
    Young R; Pailler E; Billiot F; Drusch F; Barthelemy A; Oulhen M; Besse B; Soria JC; Farace F; Vielh P
    Acta Cytol; 2012; 56(6):655-60. PubMed ID: 23207444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rationale for liquid biopsy in colorectal cancer: a focus on circulating tumor cells.
    Gazzaniga P; Raimondi C; Nicolazzo C; Carletti R; di Gioia C; Gradilone A; Cortesi E
    Expert Rev Mol Diagn; 2015; 15(7):925-32. PubMed ID: 25959553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Capture of viable circulating tumor cells in the liver of colorectal cancer patients.
    Denève E; Riethdorf S; Ramos J; Nocca D; Coffy A; Daurès JP; Maudelonde T; Fabre JM; Pantel K; Alix-Panabières C
    Clin Chem; 2013 Sep; 59(9):1384-92. PubMed ID: 23695297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility.
    Ignatiadis M; Lee M; Jeffrey SS
    Clin Cancer Res; 2015 Nov; 21(21):4786-800. PubMed ID: 26527805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor cells (CTCs) as a liquid biopsy material and drug target.
    Cai LL; Ye HM; Zheng LM; Ruan RS; Tzeng CM
    Curr Drug Targets; 2014; 15(10):965-72. PubMed ID: 25182470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's new on circulating tumor cells? A meeting report.
    Lianidou ES; Mavroudis D; Sotiropoulou G; Agelaki S; Pantel K
    Breast Cancer Res; 2010; 12(4):307. PubMed ID: 20727231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells: a multifunctional biomarker.
    Yap TA; Lorente D; Omlin A; Olmos D; de Bono JS
    Clin Cancer Res; 2014 May; 20(10):2553-68. PubMed ID: 24831278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells: clinical validity and utility.
    Cabel L; Proudhon C; Gortais H; Loirat D; Coussy F; Pierga JY; Bidard FC
    Int J Clin Oncol; 2017 Jun; 22(3):421-430. PubMed ID: 28238187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells as biomarkers in head and neck cancer: recent advances and future outlook.
    Tinhofer I; Staudte S
    Expert Rev Mol Diagn; 2018 Oct; 18(10):897-906. PubMed ID: 30199647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid biopsy: will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?
    Gingras I; Salgado R; Ignatiadis M
    Curr Opin Oncol; 2015 Nov; 27(6):560-7. PubMed ID: 26335664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.
    Kolostova K; Broul M; Schraml J; Cegan M; Matkowski R; Fiutowski M; Bobek V
    Anticancer Res; 2014 Jul; 34(7):3641-6. PubMed ID: 24982381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor Cells as Cancer Biomarkers in the Clinic.
    Chinen LTD; Abdallah EA; Braun AC; Flores BCTCP; Corassa M; Sanches SM; Fanelli MF
    Adv Exp Med Biol; 2017; 994():1-41. PubMed ID: 28560666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.